Search research articles
Contact Us
Filters
Showing results (61-70 of 130) with videos related to
Page
of 13
Sort By:
Journal of Translational Medicine
|
November 7, 2015
Open-label, multicenter, single-arm phase II DeCOG-study of ipilimumab in pretreated patients with different subtypes of metastatic melanoma
Lisa Zimmer, Thomas K Eigentler, Felix Kiecker, et al.
Journal for Immunotherapy of Cancer
|
January 20, 2018
Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial
Howard L Kaufman, Jeffery S Russell, Omid Hamid, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
|
May 7, 2019
S2k guidelines for Merkel cell carcinoma (MCC, neuroendocrine carcinoma of the skin) - update 2018
Jürgen C Becker, Thomas Eigentler, Bernhard Frerich, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
|
May 23, 2019
S2k-Leitlinie Merkelzellkarzinom (MZK, MCC, neuroendokrines Karzinom der Haut) - Update 2018
Jürgen C Becker, Thomas Eigentler, Bernhard Frerich, et al.
International Journal of Cancer
|
March 15, 2026
Real-world effectiveness and safety with nivolumab plus ipilimumab or nivolumab alone in patients with or without melanoma brain metastasis: Results from the German noninterventional NICO study
Ralf Gutzmer, Michael Weichenthal, Thomas Eigentler, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 20, 2018
Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors
Alvaro Moreira, Carmen Loquai, Claudia Pföhler, et al.
Cancer Immunology, Immunotherapy : CII
|
February 6, 2019
Early objective response to avelumab treatment is associated with improved overall survival in patients with metastatic Merkel cell carcinoma
Sandra P D'Angelo, Matthias Hunger, Andrew S Brohl, et al.
Medicine
|
November 19, 2016
Preferences of German melanoma patients for interferon (IFN) α-2b toxicities (the DeCOG "GERMELATOX survey") versus melanoma recurrence to quantify patients' relative values for adjuvant therapy
Katharina C Kaehler, Christine Blome, Andrea Forschner, et al.
BMC Cancer
|
May 30, 2021
Long-term real-world experience with ipilimumab and non-ipilimumab therapies in advanced melanoma: the IMAGE study
Stéphane Dalle, Laurent Mortier, Pippa Corrie, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 14, 2025
Clinical course of Merkel cell carcinoma: A DeCOG multicenter study of 1049 patients
Georg C Lodde, Ulrike Leiter, Anja Gesierich, et al.
Page
of 13
Search research articles
Search
Showing results (61-70 of 130) with videos related to
Sort By:
Page
of 13
Journal of Translational Medicine
|
November 7, 2015
Open-label, multicenter, single-arm phase II DeCOG-study of ipilimumab in pretreated patients with different subtypes of metastatic melanoma
Lisa Zimmer, Thomas K Eigentler, Felix Kiecker, et al.
Journal for Immunotherapy of Cancer
|
January 20, 2018
Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial
Howard L Kaufman, Jeffery S Russell, Omid Hamid, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
|
May 7, 2019
S2k guidelines for Merkel cell carcinoma (MCC, neuroendocrine carcinoma of the skin) - update 2018
Jürgen C Becker, Thomas Eigentler, Bernhard Frerich, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
|
May 23, 2019
S2k-Leitlinie Merkelzellkarzinom (MZK, MCC, neuroendokrines Karzinom der Haut) - Update 2018
Jürgen C Becker, Thomas Eigentler, Bernhard Frerich, et al.
International Journal of Cancer
|
March 15, 2026
Real-world effectiveness and safety with nivolumab plus ipilimumab or nivolumab alone in patients with or without melanoma brain metastasis: Results from the German noninterventional NICO study
Ralf Gutzmer, Michael Weichenthal, Thomas Eigentler, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 20, 2018
Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors
Alvaro Moreira, Carmen Loquai, Claudia Pföhler, et al.
Cancer Immunology, Immunotherapy : CII
|
February 6, 2019
Early objective response to avelumab treatment is associated with improved overall survival in patients with metastatic Merkel cell carcinoma
Sandra P D'Angelo, Matthias Hunger, Andrew S Brohl, et al.
Medicine
|
November 19, 2016
Preferences of German melanoma patients for interferon (IFN) α-2b toxicities (the DeCOG "GERMELATOX survey") versus melanoma recurrence to quantify patients' relative values for adjuvant therapy
Katharina C Kaehler, Christine Blome, Andrea Forschner, et al.
BMC Cancer
|
May 30, 2021
Long-term real-world experience with ipilimumab and non-ipilimumab therapies in advanced melanoma: the IMAGE study
Stéphane Dalle, Laurent Mortier, Pippa Corrie, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 14, 2025
Clinical course of Merkel cell carcinoma: A DeCOG multicenter study of 1049 patients
Georg C Lodde, Ulrike Leiter, Anja Gesierich, et al.
Page
of 13